Loading
Journal of AIDS and HIV Treatment
ISSN: 2688-7436
Olga S. Latinovic
University of Maryland School of Medicine, USA
Detection of Undiagnosed Elevated Cardiovascular Risk Biomarkers among HIV-Positive Patients on Antiretroviral Therapy (ART) in Kigali-City, Rwanda
Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
Toward Personalized Medicine for HIV/AIDS
Journal of AIDS and HIV Treatment is an international, open access journal dedicated to publish peer-reviewed articles related to clinical research, experimental studies, molecular aspects, translational studies, treatment and prevention of HIV and AIDS. Prospective authors may submit original research, reviews, case reports, commentaries, short communications, letters to the editor, clinical and epidemiological studies.
Plasma Levels of Secretory Calreticulin among HIV Infected Patients in Bauchi State
Human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome. The objective was to evaluate plasma levels of Calreticulin (CALR) in HIV positive and negative individuals.
Mental Health and Cognitive Care for Successful Aging with HIV
Globally, an estimated 4.2 million people above the age of 50 now have diagnosis of HIV (Human Immunodeficiency Virus) infection. Patients with HIV can now survive well into old age. Aging with HIV has been associated with medical illness however neuropsychiatric symptoms including cognitive decline and behavioral dysregulation has been directly associated with aging and having HIV.
Detection of Undiagnosed Elevated Cardiovascular Risk Biomarkers among HIV-Positive Patients on Antiretroviral Therapy (ART) in Kigali-City, Rwanda
Similar to other African countries, life expectancy of people living with HIV infection has improved due to access to antiretroviral therapy (ART) in Rwanda. However, both HIV infection and use of ART are associated with cardiovascular disease (CVD) risks, due to adverse changes in some biomarkers, causing dyslipidemia and other metabolic imbalances. Biomarkers for CVD risk in HIV-infected individuals taking ART, has not been well characterized in Rwanda.
Death and Transferred Out as Competing Event for Lost to Follow-up among HIV-positive Adults on ART, in Eastern Ethiopia Governmental Hospitals from January 2015 to December 2021; (Multicenter Competing Risk Regression Analysis)
Lost to follow-up (LTFU) among patients on antiretroviral therapy accounts for the most of all attrition. In Sub-Saharan Africa,there is a concern regarding high rates of LTFU and early mortality in antiretroviral therapy programs. Mortality and transferred out are the potential competing events for LTFU. Ignoring these events may give an invalid estimate by overestimating the probability of the occurrence of LTFU.
A Longitudinal Assessment of Interruptions in HIV Clinic Visits and Virologic Failure among Pregnant and Postpartum Women in the Kabeho Study
Antiretroviral therapy (ART) for women with HIV is recommended for life, yet most studies measure retention in HIV care and treatment as a binary outcome rather than patterns of intermittent clinic attendance. Pregnancy and the post-partum period are critical times to study interruptions in care, as retention among these women is particularly challenging and can affect the outcomes of both the mother and her child.
STI Characterization in Two U.S. Veterans Health Administration Healthcare Facilities During the Early COVID-19 Pandemic
This retrospective chart review of Veterans at the Maryland and Washington, D.C. VA Medical Centers showed that STI positivity ratios increased in 2020 (2018-2020). The disparity in STI risk between Black and White Veterans widened in 2020, highlighting the need for targeted evidence-based STI prevention following the COVID-19 pandemic.
Painful to Discuss: The Intersection of Chronic Pain, Mental Health, and Analgesic Use among People with HIV
This retrospective chart review study aims to identify patients in an HIV clinical setting in an area of high HIV prevalence in Atlanta, Georgia, USA who have chronic pain, analgesic prescriptions, and/or mental health diagnoses.
Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
HIV infection in pregnancy continues to be of significant clinical and public health importance [1,2]. The current statistics published by the World Health Organization (WHO) demonstrate that 38 million people are living with HIV in 2019, and 1.1 million (85%) pregnant women living with HIV received antiretroviral therapy (ARVs) during pregnancy and postpartum.
Toward Personalized Medicine for HIV/AIDS
In 2019, approximately 38 million people were infected with HIV worldwide [1]. Although there is still no cure that successfully eradicates the disease, combination antiretroviral therapy (cART) has improved to a point where undetectable viral loads have become achievable and HIV carriers often live almost normal lives with very substantially increased average life expectancies compared to historical data.
Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study
Fostemsavir (Rukobia™, ViiV Healthcare, Research Triangle Park, NC), a prodrug of the first-in-class attachment inhibitor temsavir, was developed to provide a much-needed new therapeutic option for heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) who are unable to form a suppressive regimen from remaining viable antiretroviral (ARV) agents because of multidrug resistance, contraindications, prior intolerance, or other safety considerations.
Pre-Exposure Prophylaxis (PrEP) Safety and Tolerability in Individuals ≥ 45 Years Old
Pre-exposure prophylaxis (PrEP) is a combination of antiretroviral medications, most commonly prescribed as two co-formulated antiretrovirals, taken as a single tablet daily to significantly reduce the risk of human immunodeficiency virus (HIV) infection in individuals at high risk.
Early Insights into COVID-19 in Persons Living with HIV and Cardiovascular Manifestations
At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China.
Assessment of Attitudes toward HIV and AIDS among Undergraduate Students at a Historically Black University
HIV is no longer only a public health challenge, but also a global threat with a devastating negative impact that has claimed over 35 million lives globally. In 2017, about 36.9 million people live with HIV, and 1.8 million people becoming newly infected with the disease globally [1].
Commentary – HIV-Induced Extracranial Carotid Ectasia and Stroke
HIV is a known risk factor for both ischemic and hemorrhagic stroke. Even with the widespread use of antiretroviral therapy, stroke incidence is higher in patients with HIV compared to non-HIV control subjects.
Older Versus Younger Men Who Have Sex with Men: Awareness of and Potential Barriers to the Use of Pre-Exposure Prophylaxis (PrEP) Medication to Prevent the Transmission of HIV
Men who have sex with other men (MSM) comprise the single largest group of individuals contracting HIV in the United States, accounting for more than one-half of all new HIV diagnoses.
Use of Humanized Mouse Models for Studying HIV-1 Infection, Pathogenesis and Persistence
Different humanized mouse models have been introduced to enable HIV-1 research in vivo, which has been made possible by the development of immunodeficient mouse strains.
Development of an Ultrasensitive HIV-1 DNA Detection Assay Based on an Automated πCode End-Point PCR System
Currently, around 60-75% of the HIV positive patients in developed countries on anti-retroviral therapy (ART) have undetectable plasma viral load using current diagnostic PCR assays.
HIV-1 Treatment Failure among Population Taking Antiretroviral Therapy in Ethiopia
For more than 35 years, the world has grappled with an AIDS epidemic that has claimed an estimated 35.0 million [28.9 million-41.5 million] lives and at its peak threatened global stability and security.
Assessment of Attitudes toward HIV and AIDS among Undergraduate Students at a Historically Black University
HIV is no longer only a public health challenge, but also a global threat with a devastating negative impact that has claimed over 35 million lives globally. In 2017, about 36.9 million people live with HIV, and 1.8 million people becoming newly infected with the disease globally [1].
Patient Satisfaction and Perceptions Regarding Anti-Retroviral Therapy (ART) Services in Rural Southwestern Uganda
Patient satisfaction and perception of the healthcare services received contribute to compliance with treatment guidelines, retention in care, and adherence to recommendations. This is especially so in the treatment of chronic medical conditions such as HIV/AIDS. The success of antiretroviral therapy (ART) plays a fundamental role in determining the quality of life of people living with HIV/AIDS (PLWHAs).
Known and New Routes to Neutralize HIV-1 with Camelid Single Chain Antibody Fragments
In spite of all efforts to reduce transmission of HIV-1, 1.7 million persons were infected in 2019 worldwide. Whereas in the developed countries the COVID-19 pandemic is reasonably controlled within 2 years because of the fast and successful development of vaccines, nearly 40 years after the first reported cases of AIDS due to HIV-1 and in spite of tremendous efforts to develop vaccines against HIV-1, there are still no vaccines against the virus.
Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
HIV infection in pregnancy continues to be of significant clinical and public health importance [1,2]. The current statistics published by the World Health Organization (WHO) demonstrate that 38 million people are living with HIV in 2019, and 1.1 million (85%) pregnant women living with HIV received antiretroviral therapy (ARVs) during pregnancy and postpartum.
Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study
Fostemsavir (Rukobia™, ViiV Healthcare, Research Triangle Park, NC), a prodrug of the first-in-class attachment inhibitor temsavir, was developed to provide a much-needed new therapeutic option for heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) who are unable to form a suppressive regimen from remaining viable antiretroviral (ARV) agents because of multidrug resistance, contraindications, prior intolerance, or other safety considerations.
Pre-Exposure Prophylaxis (PrEP) Safety and Tolerability in Individuals ≥ 45 Years Old
Pre-exposure prophylaxis (PrEP) is a combination of antiretroviral medications, most commonly prescribed as two co-formulated antiretrovirals, taken as a single tablet daily to significantly reduce the risk of human immunodeficiency virus (HIV) infection in individuals at high risk.
Black Women's Contribution to the HIV/AIDS Fight
After thousands of years of gender conflicts, the world now stands at the beginning of the feminine era, when women will rise to their proper standing, and the entire world will experience the harmony between men and women.
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.